Featured Research

from universities, journals, and other organizations

Acitretin Therapy May Help Reduce Nail Psoriasis

Date:
March 16, 2009
Source:
JAMA and Archives Journals
Summary:
Low-dose acitretin (a drug used to treat skin psoriasis) therapy appears to reduce nail psoriasis symptoms, according to a new report.

Low-dose acitretin (a drug used to treat skin psoriasis) therapy appears to reduce nail psoriasis symptoms, according to a new report.

Up to 78 percent of psoriasis patients experience nail psoriasis, which consists of irregular pitting, salmon-colored patches on the nail bed and onycholysis (separation of the nail from the nail bed) with erythematous (reddened and often inflamed) borders on several fingernails or toenails, according to background information in the article. "The quality of life of patients with severe nail psoriasis is affected as a result of pain and poor cosmetic appearance, subsequently leading to restricted activities of daily living," the authors write.

Antonella Tosti, M.D., of University of Bologna, Italy, and colleagues evaluated the effectiveness of low-dose acitretin therapy (0.2 to 0.3 milligrams per kilogram per day for six months) on the nails of 36 patients (27 men and nine women, average age 41 years) who had psoriasis involving only the nails. Researchers used the Nail Psoriasis Severity Index (NAPSI) to grade the severity of the condition. Higher NAPSI scores indicated more severely affected nails. Patients were followed up for at least six months after treatment.

"The mean percentages of reduction of the NAPSI score and modified NAPSI score were 41 percent and 50 percent, respectively," the authors write. "Clinical evaluation at six months showed complete or almost complete clearing of the nail lesions in nine patients (25 percent), moderate improvement in nine (25 percent), mild improvement in 12 (33 percent) and no improvement in six (11 percent)."

"Only one of the 36 patients experienced adverse effects on the nail during treatment," the authors note. All participants whose condition improved did not return to pre-treatment conditions.

"Although more studies are required to thoroughly assess the effectiveness in larger controlled subject populations, our observations suggest that low-dose systemic acitretin should be considered in the therapeutic armamentarium in the treatment of nail psoriasis," the authors conclude.

Contributing author, Dr. Romanelli, has received payments for speaking engagements from Amgen Inc., Abbott Laboratories and Genentech Inc.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tosti et al. Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis. Archives of Dermatology, 2009; 145 (3): 269 DOI: 10.1001/archdermatol.2008.600

Cite This Page:

JAMA and Archives Journals. "Acitretin Therapy May Help Reduce Nail Psoriasis." ScienceDaily. ScienceDaily, 16 March 2009. <www.sciencedaily.com/releases/2009/03/090316173323.htm>.
JAMA and Archives Journals. (2009, March 16). Acitretin Therapy May Help Reduce Nail Psoriasis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/03/090316173323.htm
JAMA and Archives Journals. "Acitretin Therapy May Help Reduce Nail Psoriasis." ScienceDaily. www.sciencedaily.com/releases/2009/03/090316173323.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins